Doc, you’re thinking of Dr. Toru Miyazaki, the Japanese immunologist at the University of Tokyo who is developing a treatment that could potentially allow cats to live into their late 20s or even reach 30 years.
And yes, there’s real science behind it!
The treatment involves a protein called AIM (Apoptosis Inhibitor of Macrophage), which plays a role in helping the body clear cellular debris, particularly in the kidneys.
Why this is exciting
Cats have a peculiar problem with AIM. Although they produce the protein, much of it remains tightly bound to immunoglobulin M (IgM), limiting its ability to help clear debris from damaged renal tubules.
Miyazaki’s research suggests that restoring this cleanup mechanism could reduce kidney injury and slow the progression of chronic kidney disease.
That’s potentially enormous because CKD is one of the major causes of morbidity and mortality in geriatric cats.
The 30-year lifespan claim, however, is a long-term aspiration, not a demonstrated result.
Current status — October 21, 2026
Awaiting regulatory approval
The drug now has a name: FeliAIM.
- June 2025: Clinical trials began at 26 veterinary hospitals in Japan.
- January 2026: A peer-reviewed study reported striking survival benefits.
- April 24, 2026: The manufacturer submitted an application for approval in Japan.
- September 2026: The drug was still under regulatory review, with a possible Japanese launch before the end of 2026. I couldn’t verify a subsequent approval.
The actual survival data
Survival at 360 days in the published exploratory study
Treated with AIM (11 cats)
80–83%
Untreated controls (15 cats)
20%
Small, non-pivotal study involving cats with advanced CKD and elevated indoxyl sulfate. These are preliminary results, not proof of a 30-year lifespan.
That’s a remarkable signal, but the study was small and nonrandomized. The larger regulatory trial’s detailed results have not yet been publicly reported.
For your veterinary practice, Doc: this is one of the more interesting potential advances in feline nephrology in years. It’s a recombinant protein therapy administered intravenously, not simply a dietary protein supplement.
The big unanswered questions are dosing frequency, long-term safety, whether treatment can prevent CKD before it begins, and whether the survival advantage holds up in larger controlled studies.
And I’d be particularly interested in the preventive application. Treating a 14-year-old cat with established CKD is one thing. Preserving renal function beginning at age 7 or 8 could be a much bigger breakthrough.
I can keep an eye on FeliAIM’s Japanese approval and eventual U.S. availability if you’d like.
